Odyssey Health, INC

Odyssey Health's agreement to distribute Davion Healthcare's BreastCheck product has been cancelled due to NeuRX Health's failure to secure necessary approvals.

Odyssey Health has finalized an agreement to acquire exclusive worldwide marketing and distribution rights for the BreastCheck non-invasive screening device.

Odyssey Health, Inc. has secured extensions for multiple promissory notes, pushing repayment deadlines into 2026 and 2027.

Odyssey Health, Inc. announced a multi-million-dollar, nine-year maintenance service contract and a financing facility of up to $25 million to support strategic growth and commercialization initiatives.

Odyssey Health, Inc. has acquired exclusive worldwide sub-licensing rights to BreastCheck, a non-invasive breast abnormality test, aiming to enter the growing breast cancer diagnostics market.

Odyssey Health, Inc. has extended the maturity date of its $870,000 promissory note with Mast Hill Fund, L.P. to April 30, 2026, and eliminated amortization payments.

Odyssey Health reports a net income of $765,890 for the quarter ended April 30, 2026, while maintaining a going concern warning due to significant accumulated deficits.

Odyssey Health, Inc. reported a reduced net loss for the first quarter of fiscal 2026 but continues to face substantial doubt about its ability to continue as a going concern due to recurring losses and negative working capital.

Odyssey Health, Inc. reported a significant net loss for the nine months ended April 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and negative cash flows.

Odyssey Health's Q2 2025 report reveals ongoing losses and a focus on securing additional funding to continue operations and product development.

Odyssey Health reported a net loss of $1.019 million for the quarter ended October 31, 2024, and faces substantial doubt about its ability to continue as a going concern.

Odyssey Health's Q3 2024 report details a significant asset sale to Oragenics, impacting financials and future strategy, alongside ongoing financial challenges.

Odyssey Health, a medical product developer, faces significant going concern doubts and funding challenges despite progress in product development and a new sub-licensing agreement.

Odyssey Health Inc. reports its full year 2024 results, including a significant gain from the sale of assets to Oragenics, while continuing to develop its medical device technologies.

Odyssey Health, Inc., a 10% owner and director of Oragenics Inc. (OGEN), has reported the complete sale of its common stock holdings in the company across two transactions in June 2025.

Odyssey Health, Inc., a 10% owner and director of Oragenics Inc. (OGEN), reported the sale of 10,000 shares of common stock across two transactions in mid-June 2025.

Christine Farrell, CFO of Odyssey Health, Inc., reports the acquisition of stock options.

Director Ricky Richardson acquired stock options for 300,000 shares of Odyssey Health, Inc. on June 28, 2024.

Director Jerome H. Casey acquired stock options for 300,000 shares of Odyssey Health, Inc.

Odyssey Health's CEO, J Michael Redmond, was granted stock options to purchase 500,000 shares of common stock on June 28, 2024.

Odyssey Health files S-1 for the resale of 18 million common shares by Mast Hill Fund, L.P., with potential for up to $25 million in future funding.

Odyssey Health Incorporated filed Amendment No. 2 to its S-1 Registration Statement, primarily to update exhibits and detail past unregistered securities issuances.

Odyssey Health Incorporated filed an amendment to its S-1 registration statement to include a legal opinion and update the exhibit index, with no changes to the preliminary prospectus.

Odyssey Health Incorporated filed an S-1 registration statement to allow Mast Hill Fund, L.P. to resell 20 million shares and potentially raise up to $25 million for general corporate purposes.

Jonathan D. Lutz has reported an amended beneficial ownership of 7.3% of Odyssey Health, Inc.'s common stock, totaling 7,239,595 shares.